USPTO serial 79298417
CELYAD ONCOLOGY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 25, 2022
- Examiner
- MAHMOUDI, MARIAM AZIZ
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CELYAD ONCOLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Cellular pharmaceutical preparations for use in oncology and cardio-vascular diseases; implants comprised of living tissues, for pharmaceutical use; pharmaceutical products, namely, products for the treatment of tumors and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T) cells for medical use; compositions comprised of white blood cells, specifically T-cells and NK-cells, for pharmaceutical use; viral vectors in the nature of biological cultures for medical use; plasmids in the nature of DNA molecules for medical use | ACTIVE | — |
| 010 | Bioreactors for medical analysis; apparatus for culture, proliferation and modification of human cells for medical purposes; apparatus for cell therapy; catheters; surgical and medical instruments for use in the diagnosis and treatment of oncology and cardio-vascular diseases; medical implants consisting of artificial materials | ACTIVE | — |
| 042 | Scientific and technological services, namely, research, analysis and testing in the field of oncology and cardio-vascular diseases; scientific research services in the field of cell therapy, oncology, immuno-oncology and in the field of medical and surgical instruments | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Celyad Oncology, Société anonyme
- Other trademarks owned by Celyad Oncology, Société anonyme
- Other trademarks owned by Celyad Oncology, Société anonyme
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named CELYAD ONCOLOGY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 13, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 25, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 1, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 1, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 25, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 25, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 9, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 9, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 20, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 1, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 1, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 1, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 1, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 1, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 22, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 21, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 21, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 24, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 24, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 20, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 19, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 16, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 4, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 30, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 26, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |